NDC 60505-6229-04 - Daptomycin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 60505-6229
- Requested NDC
- 60505-6229-04
- Package NDCs from labels
- 60505-6229-4, 60505-6229-04
- Manufacturer
- APOTEX CORP. | Qilu Pharmaceutical (Hainan) Co., Ltd.
- Effective date
- 2024-01-19
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Daptomycin - APOTEX CORP. | Qilu Pharmaceutical (Hainan) Co., Ltd. | APOTEX CORP. | Qilu Pharmaceutical (Hainan) Co., Ltd. | 2024-01-19 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 60505-6229-4 | Daptomycin | 10 mL in 1 VIAL, SINGLE-USE | INJECTION, POWDER, LYOPHILIZED, | 10 | 7 | |
| 60505-6229-4 | Daptomycin | 1 in 1 CARTON | INJECTION, POWDER, LYOPHILIZED, | 1 | 7 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 60505-6229 | DAPTOMYCIN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [APOTEX CORP.] | 7 | Current NDC, Legacy NDC, 2 package rows | 20240120_4bf6cd85-dfc8-44d4-b569-3ff27b9d3c09.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 60505-6229-4 | EA - Each | 60505-6229 | 96a6e220-8348-418d-8246-2c20ceb664c0 | 1 | 2022-03-09 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Daptomycin | DAPTOMYCIN | Aspiro Pharma Limited | e6fef9de-e357-4fa3-8839-f483edf1b4d0 | 2026-08-26 | Warnings, Adverse reactions | 403920 NWQ5N31VKK |
| Daptomycin | DAPTOMYCIN | Sagent Pharmaceuticals | 4a0ad110-e55e-4d3b-84f8-dd0b924fe2f6 | 2026-08-06 | Warnings, Adverse reactions | NWQ5N31VKK |
| Daptomycin | DAPTOMYCIN | Sagent Pharmaceuticals | 548f3559-0531-4c95-9e1d-81f81a3801f1 | 2026-07-21 | Warnings, Adverse reactions | NWQ5N31VKK |
| Daptomycin | DAPTOMYCIN | Hospira, Inc. | 1957b6ce-7382-4a7b-bf02-3595948d09c6 | 2026-05-08 | Warnings, Adverse reactions | 403920 NWQ5N31VKK |
| Daptomycin | DAPTOMYCIN | Camber Pharmaceuticals, Inc. | 1d29832c-564b-4694-842a-50aeeb823ec8 | 2026-04-23 | Warnings, Adverse reactions | 403920 NWQ5N31VKK |
| Daptomycin | DAPTOMYCIN | NorthStar RxLLC | 3c482379-4c3c-4e94-be37-213fe0d76f19 | 2026-04-23 | Warnings, Adverse reactions | 403920 NWQ5N31VKK |
| Daptomycin | DAPTOMYCIN | Camber Pharmaceuticals, Inc. | 07bc65c6-f302-4d16-9803-a8567fe76f38 | 2026-04-13 | Warnings, Adverse reactions | NWQ5N31VKK |
| Daptomycin | DAPTOMYCIN | Civica, Inc. | 1ae55ae0-d20f-4e15-b4dc-7e45c33f3152 | 2026-04-09 | Warnings, Adverse reactions | 403920 NWQ5N31VKK |
| Daptomycin | DAPTOMYCIN | Hikma Pharmaceuticals USA Inc. | 23f39005-3008-4ab1-918d-b8acb001554e | 2026-03-23 | Warnings, Adverse reactions | NWQ5N31VKK |
| DAPTOMYCIN | DAPTOMYCIN | Meitheal Pharmaceuticals Inc. | 191f0224-67b7-4945-bdcd-38d60645e38c | 2026-03-09 | Warnings, Adverse reactions | NWQ5N31VKK |
| DAPTOMYCIN | DAPTOMYCIN | Meitheal Pharmaceuticals Inc. | 278ad91e-2141-4bc1-b142-a9caca65f1bf | 2026-02-17 | Warnings, Adverse reactions | 403920 NWQ5N31VKK |
| DAPTOMYCIN | DAPTOMYCIN | Meitheal Pharmaceuticals Inc. | f5736d54-5bc2-48c6-97c6-65f7422725f0 | 2026-02-17 | Warnings, Adverse reactions | 403920 NWQ5N31VKK |
| Daptomycin | DAPTOMYCIN | BluePoint Laboratories | d6c3df37-8481-46c2-8048-199bad37c933 | 2026-01-30 | Warnings, Adverse reactions | 403920 NWQ5N31VKK |
| Daptomycin | DAPTOMYCIN | Hikma Pharmaceuticals USA Inc. | 74176769-b22e-4e41-8c56-051e15ec5fea | 2025-12-18 | Warnings, Adverse reactions | 403920 NWQ5N31VKK |
| DAPTOMYCIN | DAPTOMYCIN | Meitheal Pharmaceuticals Inc. | 4f39cddc-1cb7-41d4-a657-07f7903ee24f | 2025-12-08 | Warnings, Adverse reactions | NWQ5N31VKK |
| daptomycin | DAPTOMYCIN | BE Pharmaceuticals Inc. | 4cdf4099-db58-43b8-9fbc-afd997ccfa4b | 2025-10-24 | Warnings, Adverse reactions | 403920 NWQ5N31VKK |
| DAPTOMYCIN | DAPTOMYCIN | Accord Healthcare Inc. | 956b068f-5958-49eb-9c9f-3b6e324e77d2 | 2025-10-09 | Warnings, Adverse reactions | 403920 NWQ5N31VKK |
| Daptomycin | DAPTOMYCIN | Accord Healthcare, Inc. | f69e9306-ffac-41c9-b277-a6d784f2e341 | 2025-10-09 | Warnings, Adverse reactions | NWQ5N31VKK |
| DAPTOMYCIN | DAPTOMYCIN | Meitheal Pharmaceuticals Inc. | 7d50f20e-5e26-4cc0-ae45-830df5a46a42 | 2025-09-10 | Warnings, Adverse reactions | 403920 NWQ5N31VKK |
| daptomycin | DAPTOMYCIN | Mylan Institutional LLC | b7737862-e783-4af3-9521-ae00ed7a42aa | 2025-09-08 | Warnings, Adverse reactions | 403920 NWQ5N31VKK |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.